Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine adds to board of directors

Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins

Editas Medicine Dr Akshay VaishnawCambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors.

Dr Vaishnaw brings over 30 years of pharmaceuticals experience to the genome editing company, and currently serves as both executive vice president of research and development and chief medical officer at Alnylam Pharmaceuticals.

Prior to joining Alnylam in 2006, he worked in medical research at Biogen and held roles of increasing responsibility before becoming senior director of medical research.

Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am delighted to welcome Akshay to our board of directors.

“He has extensive clinical development experience, a passion for scientific excellence, and achieved significant accomplishments as part of the leadership team that has built Alnylam.

“We believe Akshay's perspective and advice will be invaluable as we continue to advance the organisation and drive innovative new medicines to treat genetic diseases.”

2nd August 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics